425 related articles for article (PubMed ID: 17316146)
1. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
2. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
3. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
4. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
5. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
6. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
7. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
9. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
Fishbane S; Kowalski EA
Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
[TBL] [Abstract][Full Text] [Related]
10. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
[TBL] [Abstract][Full Text] [Related]
11. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
12. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease.
Agarwal R; Rizkala AR; Kaskas MO; Minasian R; Trout JR
Kidney Int; 2007 Sep; 72(5):638-42. PubMed ID: 17622274
[TBL] [Abstract][Full Text] [Related]
13. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
14. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
15. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
16. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study.
Leehey DJ; Palubiak DJ; Chebrolu S; Agarwal R
Nephrol Dial Transplant; 2005 Jan; 20(1):135-40. PubMed ID: 15522899
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
18. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
[TBL] [Abstract][Full Text] [Related]
19. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
20. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
Zager RA
Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
